跳至主要内容
临床试验/NCT01413269
NCT01413269已完成3 期

Phase 3 Open-labeled Randomized Clinical Study of Comparing Hypofractionated and Conventional Radiotherapy for Breast Cancer Patients After Breast Conservative Surgery

Cancer Institute and Hospital, Chinese Academy of Medical Sciences7 个研究点 分布在 1 个国家目标入组 720 人开始时间: 2010年6月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
720
试验地点
7
主要终点
in-breast recurrence rate

研究概览

简要总结

Early-stage breast cancer patients treated with breast conservative surgery are enrolled in this study if they meet defined criteria. Patients are randomized into two groups: conventional fractionation radiotherapy and hypofractionated radiotherapy.The hypothesis is that conventional fractionation radiotherapy and hypofractionated radiotherapy have similar efficacy and toxicity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • histology confirmed invasive breast cancer
  • received breast conservative surgery(wide local excision and axilla dissection, or axillary sentinel node biopsy if sentinel node is negative)
  • surgical margins negative
  • primary tumor ≤5cm in the largest diameter
  • no internal mammary node or supraclavicular node metastases or distant metastasis
  • can tolerate chemotherapy,hormone therapy (if needed) and radiotherapy
  • for patients not need chemotherapy,enrollment date is required no more than 8 weeks from surgery date
  • for patients with chemotherapy first,enrollment date is required no more than 8 weeks from the last date of chemotherapy
  • patients signed written inform consent form

排除标准

  • ductal carcinoma in situ
  • prior neoadjuvant chemotherapy
  • prior breast cancer history
  • bilateral breast cancer
  • pregnant or during lactation
  • prior or concomitant malignant tumor excluded skin cancer(not malignant melanoma) and cervix carcinoma in situ
  • active collagen vascular disease
  • prior neoadjuvant hormone therapy
  • immediate ipsilateral breast reconstruction

研究组 & 干预措施

hypofractionation radiotherapy

Experimental

irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.

干预措施: radiotherapy (Radiation)

conventional fractionation radiotherapy

Active Comparator

irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.

干预措施: radiotherapy (Radiation)

结局指标

主要结局

in-breast recurrence rate

时间窗: 5 year

evidence of ipsilateral breast local recurrence confirmed by histology

次要结局

  • acute toxicity(6 months)
  • regional node recurrence rate(5 year)
  • disease-free survival(5 year)
  • overall survival(5 year)
  • late complication(3 -10 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shulian Wang

M.D.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

研究点 (7)

Loading locations...

相似试验